Once-daily oral semaglutide tablet from Novo Nordisk, FDA-approved December 2025 for weight management and cardiovascular risk reduction in adults. Self-pay $149 to $299/month by dose (checked Sept 20, 2026).
FDA-approved for
Boxed warning: Risk of thyroid C-cell tumors (see Prescribing Information). This page is not medical advice. Talk to a licensed clinician.
Verified on September 20, 2026. Source: NovoCare Pharmacy (novocare.com). Prices can change, so confirm the final price before you pay.
As little as $25/month (maximum $100/month savings; government beneficiaries excluded)
Free (NovoCare Pharmacy)
Lowest standard self-pay price per month from each manufacturer’s own pharmacy. Introductory offers and insurance prices are excluded. Medications, doses and approved uses differ, so this is a price reference, not a treatment comparison.
Wegovy tablets are a once-daily oral form of semaglutide from Novo Nordisk, approved by the FDA in December 2025. According to Novo Nordisk’s patient information, Wegovy tablets are used with a reduced-calorie diet and increased physical activity to help adults with obesity, or overweight with weight-related medical problems, lose weight and keep it off, and to reduce the risk of major cardiovascular events in adults with known heart disease and obesity or overweight. It is not known if Wegovy tablets are safe and effective in people under 18.
Self-pay prices vary by dose and were checked on September 20, 2026 on NovoCare Pharmacy. A limited-time $149 price on the 4 mg dose ended on August 31, 2026.